The efficacy and cost-effectiveness of statins in low-risk patients
- Optimise dosages and lower drug costs. Ahmed, Mohammed // GP: General Practitioner;1/21/2002, p62
Focuses on the improvement of the cost-effectiveness of drugs by dose optimization in Great Britain. Alterations in the strength of the medication to match the needed dose; Amount of savings from dose optimization of statins; Limitations of dose optimization for certain drugs.
- Switch to ezetimibe/simvastatin proves worthwhile in the UK. // PharmacoEconomics & Outcomes News;8/7/2010, Issue 609, p9
The article discusses research on the cost effectiveness of using ezetimibe/simvastatin compared with doubling statin doses for British patients with acute coronary syndromes, referencing a study by J. Reckless and colleagues published in the June 7, 2010 issue of "Value in Health."
- How does cost effectiveness change over a product's life cycle? // PharmacoEconomics & Outcomes News;6/11/2011, Issue 630, p12
The article discusses two research on the cost effectiveness atorvastatin and clopidogrel over the product life cycle, presented at the 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
- NHS study backs potent statins for first-line use. Anekwe, Lilian // Pulse;6/17/2009, Vol. 69 Issue 21, p8
The article presents a survey on cost-effective standard therapy in patients in Great Britain. It has found that to prescribe rosuvastatin was a better option over simvastatin 40 milligram. It has also strongly made a warning against ramping up simvastatin doses up to 80 milligram in a day while...
- Cost effectiveness of intensive statin therapy remains debatable. // PharmacoEconomics & Outcomes News;1/23/2010, Issue 595, p6
The article discusses research on the cost-effectiveness of atorvastatin in treating congestive heart failure and coronary heart disease, that references a study by V. M. Rosen and colleagues published in the January 1, 2010 issue of "PharmacoEconomics."
- Statins cost-effective in all diabetes. Cressey, Daniel // Pulse;2/8/2007, Vol. 67 Issue 5, p10
The article reports the findings of an analysis of landmark Cards trial in Great Britain which points the cost-effectiveness of using statins in treating patients with diabetes. Study leader Maria Raikou notes that primary prevention of cardiovascular disease with atorvastatin is cost-effective,...
- Commentary. Bryson, Chris L.; Fihn, Stephan D. // Evidence Based Medicine;Apr2007, Vol. 12 Issue 2, p58
The author comments on the study on the cost and benefits of treating patients having cardiovascular diseases with a generic statin dose in Great Britain. As stated, the analyses used both event rate and cost data available from the study population. When it comes to implications for non-British...
- Generic simvastatin would be cost effective for more people in US. // PharmacoEconomics & Outcomes News;4/4/2009, Issue 575, p1
The article discusses a study of statin cost-effectiveness in the U.S. for people at different vascular risk levels. Based on the results, the Heart Protection Study (HPS) Collaborative Group believe that guidelines should be modified to extend statin treatment to a wider population. A Markov...
- Efficacy of alternate-day versus everyday dosing of atorvastatin. Pramanik, Sushobhan; Das, Asoke Kumar; Chakrabarty, Milan; Bandyopadhyay, Susanta Kumar; Ghosh, Mainak; Dalai, Chanchal Kumar // Indian Journal of Pharmacology;Jun2012, Vol. 44 Issue 3, p362
Background: Atorvastatin has a longer duration of action than other hydroxymethylglutaryl coenzyme A reductase inhibitors. Objectives: The objective was to evaluate the efficacy of alternate day vs. daily dosing of atorvastatin for the treatment of hyperlipidemia. Materials and Methods: In this...